Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1793858 | 0.78 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL14518604 | 0.77 | HTT (0.35) | — | |
| SCHEMBL16229092 | 0.73 | TSHR (0.41) | — | |
| SCHEMBL1792512 | 0.69 | LMNA (0.37) | — | |
| SCHEMBL2349676 | 0.69 | ALDH1A1 (0.31) | — | |
| SCHEMBL21451343 | 0.69 | — | — | |
| SCHEMBL823098 | 0.67 | NPSR1 (0.34) | — | |
| SCHEMBL12831280 | 0.67 | HTT (0.33) | — | |
| SCHEMBL23052783 | 0.67 | TSHR (0.32) | CYP2D6CYP2C19 | |
| SCHEMBL21451342 | 0.67 | NAALAD2 (0.36) | CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865686-B2 | Tetracycline compounds as tyrosyl-DNA phosphodiesterase I inhibitors | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2014-10-21 | — | — | US | disclosed |
| US-20090176747-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | NATIONAL INSTITUTES OF HEALTH (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176747-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TDP1, TDP2, TARDBP | MEN1 3718/4885CYP2D6 3578/4885CYP2C19 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.